Loxicom Oral for dogs is an oral suspension for dogs contains 1.5mg of meloxicam. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Each ml contains: Active Substance: Meloxicam 1.5 mg Excipients: Sodium Benzoate 1.5 mg
Pale yellow oral suspension.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Oral use. To be administered with food or directly into the mouth. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight (i.e. 1.33 ml/10 kg bodyweight) on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e. 0.667 ml/10 kg bodyweight). For longer term treatment, once clinical response has been observed (after 4 days), the dose can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time. Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using either of the two measuring syringes provided in the package (depending on weight of dog). The syringes fit onto the bottle and have a kg-bodyweight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus for the first day, twice the maintenance volume will be required. Alternatively therapy may be initiated with Loxicom 5 mg/ml solution for injection. A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent. Avoid introduction of contamination during use.
Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do no use in dogs less than 6 weeks of age.
Special precautions for use in animals: If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolemic or hypotensive animal, as there is a potential risk of renal toxicity. Special precautions to be taken by the person administering the veterinary medicinal product to animals: People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
10ml, 32ml, 100ml, 2x100ml, 200ml polyethylene terephthalate screw bottles with HDPE/LDPE child resistant caps. Two measuring syringes, a 1ml and a 5ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs. Not all pack sizes may be marketed.
18 months- 6 months once opened
EU/2/08/090/003, EU/2/08/090/004, EU/2/08/090/005, EU/2/08/090/032, EU/2/08/090/033